July 15, 2019

To: Office of the Vermont Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

From: Sage Therapeutics, Inc.
Jeffrey Burt (Jeffrey.Burt@sagerx.com)
Senior Director, Pricing & Contracting
215 First St.
Cambridge, MA 02142

Re: Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

On June 20, 2019, Sage Therapeutics, Inc. ("Sage Therapeutics") submitted a notice, pursuant to 18 V.S.A. § 4637(b), of the release of ZULRESSO™ (brexanolone) injection CIV 5 mg/mL in the commercial market at a wholesale acquisition cost ("WAC") that exceeds the threshold set for a specialty drug under the Medicare Part D program.

Below is the additional information related to ZULRESSO that Sage Therapeutics is required to report under 18 V.S.A. § 4637(b). As Sage Therapeutics is not obligated to report information not publicly available pursuant to 18 V.S.A. § 4637(b), the below information is limited to what Sage Therapeutics has specifically released into the public domain.

18 V.S.A. § 4637(c) Reporting Requirement	**Response for ZULRESSO**
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	The initial list price for ZULRESSO in the United States is $7,450 per vial, resulting in a projected average course of therapy cost of $34,000 per patient before discounts, based on an assumption of an average of 4.5 vials used per patient. The actual number of vials used and resulting course of therapy cost per patient before discounts will vary from patient to patient and healthcare setting to healthcare setting. Sage Therapeutics has not released any of the remaining requested information in the public domain and does not believe this information is publicly available. As a result, Sage Therapeutics is limiting its response to this reporting requirement pursuant to 18 V.S.A. § 4637(b).
Estimated volume of patients who may be prescribed the drug	Sage Therapeutics has not released any of the remaining requested information in the public domain and does not believe this information is publicly available. As a result, Sage

	Therapeutics is limiting its response to this reporting requirement pursuant to 18 V.S.A. § 4637(b).
Whether the drug was granted breakthrough therapy designation by the Food and Drug Administration ("FDA") prior to final approval	ZULRESSO received FDA Breakthrough Therapy Designation on September 6, 2016.
Whether the drug was granted priority review by the FDA prior to final approval	The New Drug Application for ZULRESSO was granted Priority Review status by FDA on May 30, 2018.
The date and price of acquisition if the drug was not developed by Sage	ZULRESSO was developed by Sage Therapeutics.